Novel strategies in antibacterial drug developmentref
:
antivirulence-directed therapy
target virulent bacteria
requires discovery of a lethal target present only in virulent bacteria
vaccination directed against virulence determinants has also been proposed
this approach would prevent acquisition of antibiotic resistance genes
by non-pathogenic bacteria
genomics : new targets for inhibiting bacterial growth and variability
: block vital metabolic pathway, efflux pump inhibitors, quorum-sensing
signalling systems, hoped that mutations in the targeted gene that may
occur through drug pressure will not be compatible with viability. Identify
target gene => clone gene, express, purify and crystallize => identify
active site and screen molecule against site => test in whole bacteria.
200-400 bacterial genes are essential genes and are a priori candidates
for killing sites by inhibitors. Comparative bacterial genomics allows
further prioritization of ORFs that are conserved in pathogens but absent
in higher eukaryotes, and for which a function can often be predicted by
bioinformatics. There are several cases in which additional knowledge is
likely to increase markedly the probability of finding new macromolecular
targets. An under-explored target is the transglycosylase step of peptidoglycan
assembly in the cell wall, in which the chemo-enzymatic synthesis of the
complex lipoglycopeptide substrate, lipid II, now enables modern configurations
of high-throughput assays. In Gram-positive bacteria, it has been known
for some time that cell-surface proteins can covalently attach to peptidoglycan.
Bacterial genomic analyses have identified multiple sortases in different
pathogens. Deciphering the selectivity of sortases for groups of proteins
that end up at the cell surface might be a prelude to the screening or
design of inhibitors. Sortases should be readily accessible to ligands,
and therefore good drug targets, but it remains to be proven how responsive
they will be for bacteriostatic or bacteriocidal action. A final example
is the non-classical pathway of isoprenoid synthesis. In contrast to the
classical mevalonate pathway found in eukaryotes, many bacteria, including
clinically important pathogens, have recently been found to contain the
genes that encode a separate pathway that has deoxyxylulose-5-phosphate
as an intermediate rather than mevalonate. The 7 enzymes of the deoxyxylulose-5-phosphate
pathway are not present in humans; these enzymes are essential for lipid
I and II biosynthesis as key intermediates in peptidoglycan assembly.
tageting non-multiplying bacteria (antibiotic kills the multiplying bacteria)
: combination strategies. When antibiotic dose decreases below a threshold,
metabolism in non-multiplying bacteria starts and some of them begin to
multiply, becoming susceptible to the next dose of antibiotic
overcoming resistance : strategies to combat efflux pumps-mediated drug
resistance
apramycin, which mimics a short section of RNA, interrupts the plasmid's
replication by sticking to RNA strands that carry its genetic information.
This 'blocks' the strands, at which point the host bacterium categorizes
the plasmid as a foreign body and ejects it. Apramycin is not likely to
be used in clinical trials, because it is quite toxic. But now that the
chemists have proved how it works, they are looking for other molecules
that could do the same job without causing problems for the patient.
Lancet or phenol coefficient : a measure of the bactericidal activity
of a chemical compound in relation to phenol.
The test is standardized (Rideal-Walker method, U. S. Department of Agriculture
method). The coefficient is calculated by dividing the concentration of
the test compound at which it kills the test organism in 10 minutes, but
not in 5 minutes, by the concentration of phenol that kills the organism
under the same conditions. It can be determined in the absence of organic
matter, or in the presence of a standard amount of added organic matter.
Woods-Fildes theory : the theory that the antibacterial activity
of at least some chemotherapeutic drugs (especially the sulfonamides) is
a consequence of a competitive inhibition of essential metabolic reactions
of the microorganism.
isoniazid / isoniazide (INH) / isonicotinic
acid hydrazide(INAH®, Nydrazid®,
Rifamate®,
...) is a pro-drug, which, after activation by the mycobacterial katG-encoded
catalase peroxidase, reacts nonenzymatically with NAD+ and NADP+
to generate several isonicotinoyl adducts of these pyridine nucleotides
:
the acyclic 4S isomer of isoniazid-NAD, targets the inhA-encoded
enoyl-ACP
reductase, an enzyme essential for mycolic acid biosynthesis in Mycobacterium
tuberculosis. It inhibits pyridoxal phosphorylation to vitamin B6
(Mycobacteria cells contain low levels of such a kinase) : so pyridoxine-dependent
reactions are inhibited (e.g. enoyl-ACP reductase of fatty acid synthase
(FAS) II, which converts
D2-unsaturated
to saturated fatty acids on the pathway to mycolic acid biosynthesis).
It should be co-administered with vitamin
B6 / pyridoxine
to minimize adverse side effects from pyridoxal kinase inhibition.
the acyclic 4R isomer of isoniazid-NADP inhibits the M. tuberculosisdihydrofolate
reductase (DHFR), an enzyme essential for nucleic acid synthesis. This
biologically relevant form of the isoniazid adduct is a subnanomolar bisubstrate
inhibitor of M. tuberculosis DHFR. Expression of M. tuberculosis
DHFR in Mycobacterium smegmatis mc2155 protects cells against growth
inhibition by isoniazid by sequestering the drugref.
ethionamide (Trecator-SC®)
inhibits the acetylation of isoniazid in vitro.
prothionamide
pyrazinamide (PZA) (pyrazine analog
of nicotinamide) inhibits mycobacterial fatty acid synthase (FAS) I, involved
in mycolic acid biosynthesis.
D-ethambutol hydrochloride
(Myambutol®).
It blocks arabinosyl transferases involved in synthesis of lipoarabinomannan
(LAM)
and mycolic acids. It is the only chemotherapeutical effective on Mycobacterium
marinum.
Side
effects : visual disturbances
daptomycin (Cidecin®, Cubicin®)
: rapdily bactericidal, i.v. only, may cause myalgia, efficacy for bacteremia/endocarditis
not demonstrated
riminophenazines :
B663 / clofazimine / clofazamine (Lamprene®)
inhibits Na+/K+ ATPase and acts as an immunosuppressor
B669
b-lactams have been introduced in 1940
:
penicillins : tetrahydrothiazole-containing
(penem group) compounds that irreversibly
inhibit the transpeptidase activity of penicillin-binding protein (PBP)
3. 1 international unit of penicillin : the specific penicillin
activity contained in 0.6 mg of the international
standard sodium salt of penicillin II or G.
natural penicillins(Gram
+ve Bacteria and Neisseria gonorrhoeae).
Resistance to penicillin today occurs in as many as 80% of all strains
of Staphylococcus aureus : surprisingly, Streptococcus pyogenes
has never fully developed resistance to penicillin !
semisynthetic penicillins (Gram -ve rods).
A mold produces the main part of the molecule (6-aminopenicillanic acid)
which can be modified chemically by the addition of side shains. Resistant
to b-lactamase.
Side effects : type
I,
type
II,
type
III
and type
IV
hypersensitivities. Before the initiation of cephalosporin therapy, skin
testing should be performed for patients with a suspected history of IgE-mediated
reactions to penicillinsref.
The rate of cross-reactivity of > 10% between penicillins and cephalosporins
has not been well established. 3 retrospective clinical studies reported
rates of reaction to carbapenems of 9 to 11%
among inpatients with a reported penicillin allergyref1,
ref2,
ref3.
An earlier study reported that of 20 subjects with a positive penicillin
skin test, 10 reacted to an imipenem reagentref.
oxacephems (oxacephem group) : effective
against Gram +ve and
Gram -ve Bacteria, penicillinase-resistant.
latamoxef
moxalactam (Moxam®)
cephalosporins (Gram
+ve and Gram
-ve Bacteria) (from 7-aminocephalosporanic
acid).
Cephem
group. They tend to be resistant to
b-lactamases/penicillinases
from S. aureus. They bind PBP3.
carbapenems (Gram
+ve cocci and
Gram -ve rods, P.aeruginosa, anaerobes, Enterococci)
(the N atom in the penem group of penicillin is substitued by a C atom
=> carbopenem group). They arise from modifications
of the chemically unstable thienamycin.
Parenteral administration.
imipenem (IPM) / MK
0787 / N-formimidoiyl thienamycin + cilastatin
(IPM/CS) (an inhibitor of renal dihydropeptidase
I (DHP-I)-mediated hydrolysis in proximal renal tubule) (Imipem®,
Primaxin®,
Tienem®). As it is a zwitterion it
can penetrates the outer membrane in Gram -ve Bacteria.
The trans-hydroxyethil side chain differs from the cis-aminoacyl
side chain in penicillins and so this molecule is not a substrate for
b-lactamase.
It binds PBP a/Ib.
panipenem + betamipron
(PAPM/BP) (Carbenin® + betamipron) : to inhibit panipenem
uptake into the renal tubule and prevent nephrotoxicity
biapenem (BIPM) is more stable than imipenem,
meropenem and panipenem to hydrolysis by human renal DHP-I, and therefore
does not require the coadministration of a DHP-I inhibitor.
b-lactamase / penicillinase competitive irreversible
inhibitors (they are effective only if coupled to a penicillin whose
pharmacokinetics is identical) :
glycopeptides (heptapeptide-attached sugars) have been introduced
in 1958 (Gram +ve Bacteria)
vancomycin group
vancomycin
hydrochloride (Lyphocin®,
Vancocin®,
Vancoled®)
inhibits both transglycosylation and transpeptidation reactions during
peptidoglycan assembly: it makes 5 hydrogen bonds to the -D-Ala-D-Ala
dipeptide terminus of each uncrosslinked peptidoglycan side chain, inhibiting
both the transglycosilase and transpeptidase activity of PBPs. Nowadays
vancomycin-resistant
Enterococci
(VRE)
and vancomycin-resistant
Staphylococcus
aureus (VRSA)
(MBC > 32 mg/mL) appeared thanks to a plasmid-coded
enzyme that creates -D-Ala-D-lactate
termini, resulting in the loss of 1 hydrogen bond that significantly reduces
the binding constant ! The VanA strains are resistant to both vancomycin
and teicoplanin, while the VanB strains
are resistant to vancomycin only.
Side effects : nephrotoxicity, histamine-mediate
"red-man
syndrome"
(anaphylactoid reaction). Cross-resistance to glycopeptides can arise from
use of avoparcin as growth promoter in animal feeding.
oritavancin / LY333328
teicoplanin group : N-methylLeu in 1 and Lys in 3 are replaced
by substituted phenylGlys
teicoplanin
(Targocid®, Targosid®) (a lipoglycopeptide
less toxic than vancomycin)
ristocetin
(it also binds to vWF (which in fact is a.k.a. ristocetin cofactor) causing
human platelets aggregation)
dalbavancin
eremomycin
BRL 47761
ramoplanin (a glycolipodepsipeptide consisting
of 17 amino acids cyclized to a macrolactone) inhibits transpeptidase activity
of PBPs
bacitracin
zinc (AK-Tracin®,
Baci-IM®, Baciferm®; Polysporin®
in combination with polymixin B; Bimixin®
in combination with neomycin; Neosporin®
in combination with both neomycin and polymixin
B) (Gram +ve
Bacteria) needs
a divalent cation (Mg2+, Zn2+, Co2+, Ni2+
or Cu2+) to bind the undecaprenol-P-P and preventing it from
being dephosphorylated by a membrane pyrophosphatase. It has a high kidney
toxicity which precludes its systemic use. It is present in many topical
antibiotic preparations, and since it is not absorbed by the gut, it is
given to "sterilize" the bowel prior to surgery.
D-cycloserine (Seromycin®)
(Gram -ve and Gram +ve
Bacteria)
(from Streptomyces orchidaceous) enters bacterial cells by means
of an active transport system for Gly and can reach a relatively high intracellular
concentration inhibiting Ala racemase and D-Ala-D-Ala
synthetase. Side effects : as it is fairly
toxic (NMDA-R
partial agonist) it has limited use as a secondary drug for TBC.
spirocyclohexene
griseofulvin
inhibits microtubule formation in mitotic spindle. It may act as a photosensitizer.
antibacterial interfering with
cell membrane integrity : these antibiotics disorganize the structure
or inhibit the function of bacterial membranes. However, due to the similarities
in phospholipids in eubacterial and eukaryotic membranes, this action is
rarely specific enough to permit these compounds to be used systemically.
cyclic polypeptides
polymyxin.
Effective mainly against Gram -ve Bacteria
: usage is usually limited to topical usage and is occasionally given for
UTIs caused by Pseudomonas strains that are gentamicin-, carbenicillin-
and tobramycin-resistant. The balance between effectiveness and damage
to the kidney and other organs is dangerously close, and the drug should
only be given under close supervision in the hospital.
polymixin B sulfate (a mixture of polymixin
B1 and B2) (Aerospin®; Polysporin®
in combination with bacitracin; Neosporin®
in combination with bacitracin and neomycin;
Neosporin® in combination with gramicidin and neomycin;
Polytrim® in combination with trimethoprim)
binds to the lipid-A portion (the hyppo) of LPSref
polymixin E / colistin (Acetylcolistin®,
Colisticina®, Colistin-600®, Coly-Mycin-S®,
Multimycine®) (bactericidal)
from Aerobacillus colistinus
polyene : inhibits sterols present in cell
wall-less Bacteria, but they are mainly used as antifungal
agents.
platensimycin, a previously unknown
class of antibiotics produced by Streptomyces platensis. Platensimycin
demonstrates strong, broad-spectrum Gram-positive antibacterial activity
by selectively inhibiting cellular lipid biosynthesis. This anti-bacterial
effect is exerted through the selective targeting of b-ketoacyl-(acyl-carrier-protein
(ACP)) synthase I/II (FabF/B) in the synthetic pathway of fatty acids.
Direct binding assays show that platensimycin interacts specifically with
the acyl-enzyme intermediate of the target protein, and X-ray crystallographic
studies reveal that a specific conformational change that occurs on acylation
must take place before the inhibitor can bind. Treatment with platensimycin
eradicates Staphylococcus aureus infection in mice. Because of its
unique mode of action, platensimycin shows no cross-resistance to other
key antibiotic-resistant strains tested, including MRSA, VISA and VRE.
Platensimycin is the most potent inhibitor reported for the FabF/B condensing
enzymes, and is the only inhibitor of these targets that shows broad-spectrum
activity, in vivo efficacy and no observed toxicityref.
macrolides have been introduced in 1952
(against most Bacteria ; bactericidal
for a few Gram +ve Bacteria) : macrocylic
(12÷22 carbon atoms) lactones linked through glycoside bonds with
amino sugars. Binding to the rRNA 23S (P8 protein ?) in the 50S ribosomal
subunit inhibits elongation of the protein by peptidyl transferase or prevents
translocation of the ribosome or both.
erythromycin base (E-Mycin®,
Ilotycin®,
...), estolate (Ilosone®),
gluceptate (Ilotycin Gluceptate®), ethylsuccinate (E.E.S.®,
...) + sulfisoxazole or lactobionate (Erythrocyn Lactobionate-I.V.®)
; Benzamycin®, Persa-Gel®, ... in combination
with benzoyl peroxide.
From Streptomyceserythreus : not effective
against Enterobacteriaceae. Bactericidal in
vitro at high concentrations.
spiramycin (Rovamycine®,
Ulcar®) for treatment of toxoplasmosis and cryptosporidiosis
Cross-resistance to macrolides can arise from use of tylosin and
virginiamycin
as additives in animal feeding.
third-generation macrolides / 3-ketolides (a 3-keto group replacesL-cladinose
group of macrolides)
telithromycin (Ketek®)
is 99% effective in vitro against Streptococcus
pneumoniae.
i.v. only, may cause nausea and vomiting, and acute
hepatitisref.
It inhibits secretion of IL-1b and TNF-aref
clindamycin (Cleocin®,
Dalacin C®) pediatric (Cleocin Pediatric®),
topical (Cleocin T®) or topical phosphate (Cleocin Phosphate®,
Actiza®) is 7-chloro-7-deoxylincomycin, effective against
Gram
+ve Bacteria and Gram -ve Neisseria,
Hemophilus influenzae,Bacteroides
spp.).
Velac® in combination with tretinoin.
Cross-resistance to lincosamides can arise from use of tylosin and
virginiamycin
as additives in animal feeding.
streptogramins
(introduced in 1962) bind 50S impairing both early peptide chain elongation
and late peptide chain extrusion => bacteriostatic.
They are a mix of :
A (macrolide)
dalfopristin
B (cyclic peptide)
quinupristin
pristinamycin / RP 59500 = quinupristin
+ dalfopristin (Q/D) (Synercid®) : they are semisynthetic
derivatives of pristinamycins.
i.v. only, not active against E.faecalis, efficacy for bacteremia/endocarditis
not demonstrated
Cross-resistance to streptogramins can arise from use of tylosin
and virginiamycin as additives in animal feeding.
fusidic acid (against
Gram
+ve Bacteria;
bactericidal
in vitro at high concentrations) (from Fusidium coccineum)
inhibits EF-G
viomycin (Viocin®) : a basic
polypeptide antibiotic administered intramuscularly (along with other drugs)
in the treatment of Mycobacterium
tuberculosis.
May cause ototoxicity
phenicols / phenyl propanoids have been
introduced in 1949: effective against Gram +ve and Gram -ve cocchi and
Salmonella
typhi
chloramphenicol
(currently it is produced entirely by chemical synthesis) (AK-Chlor®,
Chloromycetin®, Chloroptic®, Ocu-Chlor®;
Colbiocin® in combination with rolitetracycline
and sodium colistimetate) inhibits the bacterial enzyme peptidyl transferase
in the 50S subunit
Side effects : since mitochondria probably
originated from prokaryotic cells and have 70S ribosomes, they are subject
to inhibition. The eukaryotic cells most likely to be inhibited by chloramphenicol
are those undergoing rapid multiplication, thereby rapidly multiplying
mitochondria.
such cells include the blood forming cells of the bone marrow, the inhibition
of which could present as acquired
aplastic anemia
in 1:50,000. Bone marrow toxicity was recognized to be associated with
chloramphenicol in 2 ways:
a dose-dependent reversible marrow depression that disappears when the
drug is stopped
an idiosyncratic reaction that causes irreversible marrow failure (albeit
quite rarely) that is not dose-dependent and may occur at quite low drug
levels. It should be noted that cases of the idiosyncratic reaction have
been described following the use of chloramphenicol eye drops
in newborns it may cause gray syndrome
(a potentially fatal condition seen in neonates, particularly premature
infants, characterized by an ashen gray cyanosis, listlessness, weakness,
and gray syndrome, a potentially fatal condition seen in neonates,
particularly premature infants, due to a reaction to chloramphenicol, characterized
by an ashen gray cyanosis, listlessness, weakness, and systemic
arterial hypotension)
due to inadequate glucuronidation with drug accumulation.
Chloramphenicol was a commonly used antibacterial agent in the 1950s and,
like other antimicrobials in use today, was commonly used in situations
where no specific antibiotic is required (such as in a viral respiratory
infection). Now it is seldom used in human medicine except in life-threatening
situations (e.g. typhoid fever). R plasmid-encoded resistance gene = chloramphenicol
acetyltransferase(CAT). The only antimicrobial whose enteric
absorption (palmitate) is better than parenteral absorption (succinate)
In Jan 2002, chloramphenicol was detected in animal feed in Europe.
This contamination was traced to fish/seafood products coming from the
Far East. A commentary from the Chinese Ministry of Agriculture on
the "Draft Report for the Residue Control in Live Animals and Animal Products
by EC Inspection Mission to China"ref
mentions that chloramphenicol was discontinued from the Chinese Veterinary
Pharmarcopoeia in 2000. An investigation into the contamination of shrimp
revealed that 'the prawn-peeling workers had not worn protective gloves
in the past, causing an itchy symptom on their hands, so some of
the workers used chloromycetin (chloramphenicol) to treat their hands in
order to avoid the itching, and, as a result, the prawns were polluted".
The 2002 FDA report regarding chloramphenicol testing in imported seafoodref
contains this discussion: "Until recently, the sensitivity of the methodology
to detect chloramphenicol in shrimp could find the drug down to 5 parts
per billion (ppb). Recently, Canada, and the European Union (EU), have
refined their methods to detect even lower levels, and, have taken action
on food products from China and Viet Nam found to be contaminated by chloramphenicol.
The FDA has modified its methodology to confirm chloramphenicol levels
in shrimp and crayfish to 1ppb and is further modifying the methods to
detect 0.3 ppb, which will place the U.S. methodology in line with Canada
and the EU. The new methodology for testing for chloramphenicol to the
level of 1 ppb will be used to test imported shrimp and crayfish that are
suspected to contain chloramphenicol. FDA will detain, and refuse entry
to, any product it identifies, and confirms, as containing chloramphenicol".
On 5-6 Jun 2002, a senior delegation of Chinese officials met with the
FDA to discuss the issue of chloramphenicol residues in shrimp and crayfish.
The delegation informed the FDA that, on 5 Mar 2002, China banned the use
of chloramphenicol in animals and animal feeds. They also informed
the FDA that they are initiating testing of shrimp, crayfish, and other
animal-derived foods intended for export, to ensure the absence of chloramphenicol
and other drug residues. The FDA and China exchanged information on testing
methodologies. The FDA informed the Chinese officials that the Agency would
take enforcement action against products found to be in violation.
tiamphenicol
florfenicol (Aquaflor®
and Nuflor®)
pleuromutilin (Econor®)
: a natural antibiotic diterpene that binds to the ribosomal peptidyl
transferase centre (PTC) of the 50S ribosomal subunit with its tricyclic
mutilin core positioned in a tight pocket at the A-tRNA binding siteref
and interacts with domain V of 23S RNAref.
It is effective against resistant mycoplasma infection in immunocompromised
patientsref
azamulin [14-O-(5-(2-amino-1,3,4-triazolyl)thioacetyl)-dihydromutilin]
is an azole derivativeref
tiamulin / 81.723 HFU is used in the control
and treatment of veterinary gram-positive and gram-negative pathogens,
with a particular emphasis on infections in swineref.
It has exceptional activity (MIC < 1 µg/ml) against anaerobic
bacterial species, intestinal spirochetes, and Mycoplasma sppref
nocathiacins are cyclic thiazolyl peptides
with inhibitory activity against gram-positive bacteria
BMS-249524 (nocathiacin I), identified from screening a library
of compounds against a multiply antibiotic-resistant Enterococcus faecium
strain, was used as a lead chemotype to obtain additional structurally
related compounds
2 more water-soluble derivatives, BMS-411886 and BMS-461996ref
The 23S rRNA A2058G alteration mediates macrolide,
lincosamide,
and streptogramin B resistance in the bacterial
domain and determines the selectivity of macrolide antibiotics for eubacterial
ribosomes, as opposed to eukaryotic ribosomes. However, this mutation is
associated with a disparate resistance phenotype: it confers high-level
resistance to ketolides in mycobacteria but only marginally affects ketolide
susceptibility in streptococci. Mutational alteration of the polymorphic
2057-2611 base pair from A-U to G-C in isogenic mutants of Mycobacterium
smegmatis significantly affects susceptibility to ketolides but does
not influence susceptibility to other macrolide antibiotics. In addition,
the 2057-2611 polymorphism determines the fitness cost of the 23S rRNA
A2058G resistance mutation. Polymorphic nucleotides mediate the disparate
phenotype of genotypically identical resistance mutations and provide an
explanation for the large species differences in the epidemiology of defined
drug resistance mutationsref.
tetracyclines (bacteriostatic)
: products of the aromatic poliketide biosynthetic pathway in Streptomyces,
act
by binding the 30S subunit and blocking the binding of aminoacyl tRNA to
the A site on the ribosome. As most Bacteria possess an active transport
system for tetracycline that allows intracellular accumulation of the antibiotic
at concentrations 50 times as great as that in the medium, a blood level
which is harmless to animal tissues can halt protein synthesis in invading
Bacteria.
doxycycline / doxycyclin (Bassado®,
Doxymycin®, Doryx®, Vibra®,
Vibra-Tabs™, Vibramycin®, ...) does not cause the photosensitizing
reaction that may occur with conventional tetracycline. Divalent cations,
gluten products, and calcium do not materially interfere with its absorption.
Since doxycycline is a highly lipid-soluble antimicrobial, a loading dose
is necessary for optimal results. Therefore, for moderate or severe infections,
the usual dose, given intravenously or orally, should be doubled for 72
hours and then reduced to the usual dose (ie, 200 mg every 12 hours reduced
to 100 mg every 12 hours). The entire dose (intravenous or oral) may be
given once daily. Doxycycline should be taken with food and should not
be given to pregnant patients or young children
lymecycline (Tetralysal®)
methacycline (Rondomycin®)
minocycline (Minocin®,
...) is 10-folds more lipid-soluble than conventional tetracycline whereas
doxycycline is only 5-folds more lipid-soluble. The clinical importance
of this characteristic is that minocycline has particularly good tissue
penetration and excellent CNS penetration. It is effective also against
MRSA. Food and divalent cations interfere minimally or not at all with
oral absorption, and photosensitizing reactions are rare. Because of its
high lipid-solubility, the drug is maintained in high concentrations in
middle ear fluid; thus, it has been implicated in vestibular side effects.
It should not be given to pregnant patients or young children.
Some newly discovered members of the tetracycline family (e.g. chelocardin)
have been shown to act by inserting into the bacterial membrane, not by
inhibiting protein synthesis.
Side effects : contraindicated during
pregnancy and before age 8; renal toxicity (75%), hepatotoxicity, neurotoxicity,
systemic
arterial hypertension,
hirsutism,
gingival hyperplasia, GI toxicity, Steven-Johnsons's
syndrome
glycylcyclines are tetracycline derivatives
tigecycline / GAR936 : not transported
by the tetracycline efflux pumps (Staphylococcus
aureus, including MSSA, GISA, MRSA, Streptococcus pneumoniae,
includnig PRSP, VRE, Acinetobacter, Bacteroides fragilis, Acinetobacter,
Enterobacter; inactive against Proteus spp. and P.aeruginosa).
Serum levels sometimes lower than the MIC, but high tissue distribution
far above the MIC, low inhibitory quotient in the blood but a high inhibitory
quotient in tissue. Nausea and vomiting is the most commonly reported adverse
eventref.
Appropriate targets :
peritonitis, but in combination therapy if suspicion of Pseudomonas
involvement (e.g. postoperative peritonitis, peritonitis treated with antibiotics
before surgery)
nosocomial pneumonia (post-operative pneumonia, early-onset VAP, VAP due
to Enterobacter, Acinetobacter)
severe community-acquired pneumonia
complicated skin and skin tissue infections (postoperative cellulitis)
infections with resistant Gram-positive pathogens (VRE, MRSA, GISA, VRSA)
infections with resistant Gram-negative pathogens (Enterobacter, Acinetobacter)
catheter-related bacteremia ?
endocarditis ?
aminoglycosides have been introduced
in 1950 (against Gram -ve Bacteria
and just a little Gram +ve Bacteria).
They bind to the S12 (a.k.a. P10) protein in the 30S subunit of the bacterial
ribosome blocking the binding of initiator N-fMet- tRNAMet
to the ribosome and preventing the normal dissociation of ribosomes into
their subunits, leaving them mainly in their 70S form, impairing polysomes
formation. It stabilizes aa-tRNA on the ribosome both with a cognate and
with a near-cognate codon in the A site by altering the rates of GTP hydrolysis
by elongation factor Tu (EF-Tu), resulting in almost identical rates of
GTP hydrolysis and virtually complete loss of selectivity. The difference
in spelling (-micin or -mycin) reflects the isolation from
Streptomyces
spp. or Micromonospora spp., respectively. They can be classified
according to their aminocyclitol :
only topical PO use before GI tract surgery (no if hemorrhages are suspected
!) : very toxic when administered IV !
kanamycin
sulfate (Kantrex®) : restricted spectrum, but if given IV
it is effective even against Staphyloccous aureus
intermediate spectrum
neomycin
sulfate (Mycifradin®, Neo-Fradin®;
Neosporin G.U. Irrigant® in combination
with polymixin B; Neosporin®
in combination with bacitracin and polymixin
B; Neosporin® in combination with gramicidin
and polymixin B) or undecylenate
paramomycin (Humatin®)
: effective even against Staphyloccous aureus
broad spectrum
amikacin / BBK8 (Amikin®)
netilmicin (Netromycin®)
: semisynthetic
sisomicin / thiostrepton (Siomycin®)
derived from Micromonospora inyoensis, closely related to the C1a
component of the gentamicin complex; it is bactericidal for many gram-negative
and some gram-positive organisms, having a range of activity similar to
that of gentamicin.
sisomicin sulfate : the sulfate salt of sisomicin, used in the treatment
of infections caused by susceptible gram-negative organisms; administered
intravenously or intramuscularly.
Resistance genes : aminoglycoside acetylases
(AAC), adenylylases (AAD), and phosphorylases (APH).
Side effects :
reversible acute
renal failure
lasting up to 20 days after suspension (evaluate [Ala-aminopeptidase]urine]
damage to the vestibulocochleary (auditory) nerves => permanent deafness
and/or temporaneous dizziness lasting 2-6 months. gentamicin-induced hearing
loss averages 8% for a short course of therapyref
but may be higher in developing countries, where aminoglycosides are frequently
the only affordable antibiotics and are sold over the counter. No therapy
presently exists to prevent ototoxicity. Animal models suggest that ototoxicity
is caused by reactive oxygen species and is attenuated by antioxidantsref.
Salicylate is a clinically promising antidoteref
that can be administered as aspirin. 195 patients received 80 to 160 mg
of gentamicin twice daily by intravenous infusion (generally for 5 to 7
days) and were randomly assigned to receive 14 days of supplementation
either with 3 g of aspirin per day, divided into 3 doses (89 patients),
or with placebo. The incidence of hearing loss in the placebo group was
within the anticipated range (13%) but was significantly lower in the aspirin
group (3%). The efficacy of the gentamicin therapy was not affected by
the administration of aspirin. However, gastric symptoms were more common
in the aspirin groupref.
oxazolidinones (introduced in 2000)
inhibit the bacterial pre-translational initiation complex formation =>
bacteriostatic
linezolid (Zyvox®) i.v. and
p.o. Side effects : thrombocytopenia, hyperlactatemia,
metabolic acidosis, and peripheral neuropathy are adverse effects related
to the drug's capacity for interference with mitochondrial functionref;
efficacy for bacteremia/endocarditis not demonstrated
hexamethylenamine / hexamine / methenamine mandelate and hippurate
(Urex®, Hiprex®, Mandelamine®)
: the compound decomposes in water at acidic pH according to the following
reaction :
quinolones have been introduced in 1962
(bactericidal against Gram
-ve Bacteria) at low doses inhibit the religation of the
doubly cleaved DNA whose 5' ends are tethered on 2 Tyr residues in type
II bacterial topoisomerases [both DNA gyrase (1 Tyr per GyrA subunit
in the active (GyrA)2(GyrB)2 tetramer) and DNA topoisomerase
IV], while at high doses (e.g. those present in urine) inhibit N-methyltransferase
1st generation quinolones : urinary antiseptic, uneffective
against Pseudomonas aeruginosa
2nd generation quinolones : urinary antiseptic, effective
even against Pseudomonas aeruginosa
cinoxacin (Cinobac®, Cinoxacin®)
flumequine
novobiocin (Albamycin®)
binds the B subunit of DNA gyrase inhibiting ATP hydrolysis
pipemidic acid (Dolcol®,
Pipram®)
rosoxacin (Eradacil®)
3rd generation / 6-fluoroquinolones
(FQ) : systemic distribution (expecially used against bacterial respiratory
and UTIs, prostatitis, osteomyelitis,
and Salmonella typhi).
Fluoroquinolones, broad-spectrum antibiotics that are widely perceived
to have favorable adverse-effect profiles, have become the most prescribed
antibiotics in the USAref.
From 1995 to 2002, the number of fluoroquinolone prescriptions in the USA
increased by a factor > 3, reaching about 22 million prescriptions per
yearref.
The available fluoroquinolones have well-established differences in antimicrobial
activity, but their disparate adverse-effect profiles are increasingly
being recognized. Serious adverse events have led to the withdrawal or
restriction of several fluoroquinolones in recent yearsref
ciprofloxacin (Ciloxan®,
Cipro®, Ciproxin®) : PO, i.v.. In European
ICUs it is effective against 89% of MSSA, 7% of MRSA, 92% of E.coli,
78% of Enterobacter spp., and 73% of P.aeruginosaref.
Ciprofloxacin is absorbed from the gastro-intestinal tract. Oral bioavailability
is approximately 70% and a peak plasma concentration is achieved 0,5 to
2 hours after oral dosing. Absorption may be delayed by the presence of
food, but is not substantially affected overall. The plasma half-life is
about 3,5 to 4,5 hours and there is evidence of moderate accumulation.
Half-life may be prolonged in severe renal failure and to some extent in
the elderly. Plasma protein binding ranges from 20 to 40%. Ciprofloxacin
is widely distributed in the body and tissue penetration is extensive.
It appears in the cerebrospinal fluid, but the concentrations are only
about 10% of those in the plasma when the meninges are not inflamed. Ciprofloxacin
crosses the placenta, and is distributed into the breast milk. High concentrations
are achieved in the bile. Ciprofloxacin is eliminated principally by urinary
excretion, but non-renal clearance may account for about a third of elimination
and includes hepatic metabolism, biliary excretion, and possibly transluminal
secretion across the intestinal mucosa. Urinary excretion is by active
tubular secretion as well as glomerular filtration and is virtually complete
within 24 hours. About 40 to 50% of an oral dose is excreted unchanged
in the urine and about 15% as metabolites Faecal excretion over 5 days
has accounted for 20 to 35% of an oral dose. At least 4 active metabolites
have been identified. Oxociprofloxacin appears to be the major urinary
metabolite, and sulphociprofloxacin is the primary faecal metabolite.
Only small amounts of ciprofloxacin are removed by haemodialysis or peritoneal
dialysis.
ofloxacin (Floxin®, Ocuflox®,
Tarivid®)
long-acting (1 / die) and broad spectrum
fleroxacin (Megalone®)
lomefloxacin (Maxaquin®)
pefloxacin (Peflocin®)
temafloxacin (Omniflox®),
recalled because of hemolysis, renal failure, and hypoglycemiaref
(Rubinstein E. History of quinolones and their side effects. Chemotherapy
2001;47:Suppl 3:3-8, 44)
uvofloxacin
clinafloxacin
difloxacin (Dicural®)
gatifloxacin (Tequin®)
: limited data suggest that as compared with other currently available
fluoroquinolones, gatifloxacin (Tequin, Bristol-Myers Squibb) may be uniquely
associated with increased risks of both hypoglycemia and hyperglycemiaref1,
ref2,
ref3,
ref4,
ref5,
ref6,
ref7,
ref8,
ref9,
ref10,
ref11,
ref12,
ref13,
ref14,
ref15
(Tailor SA, Simor AE, Cornish W, Phillips E, Knowles S, Rachlis A. Analysis
of spontaneous report of hypoglycemia and hyperglycemia associated with
marketed systemic fluoroquinolones made to the Canadian Adverse Drug Reaction
Monitoring Program. Can J Hosp Pharm 2004;57:12-17; Frothingham R. Gatifloxacin
associated with a 56-fold higher rate of glucose homeostasis abnormalities
than comparator quinolones in FDA Spontaneous Reporting Database. In: Program
and abstracts of the 44th Interscience Conference on Antimicrobial Agents
and Chemotherapy, Washington, D.C., October 30–November 2, 2004. Washington,
D.C.: American Society for Microbiology, 2004:19; Létourneau G,
Morrison H, McMorran M. Gatifloxacin: hypoglycemia and hyperglycemia. Can
Adverse React Newsl 2003;13(3):1-2). Although the mechanism of these apparently
competing adverse effects is not fully understood, studies in animals suggest
that although gatifloxacin can promote insulin release and hypoglycemia
by blocking the ATP-sensitive potassium channels of pancreatic islet cells,
it can also trigger the vacuolation of pancreatic b
cells, leading to reduced insulin levels and hyperglycemiaref1,
ref2,
ref3,
ref4.
Evidence that gatifloxacin causes dysglycemic effects in humans consists
of data from case reports, small studies in healthy volunteers or hospital
inpatients, and one small post-marketing studyref1,
ref2,
ref3,
ref4,
ref5
(Grasela DM, Lacreta F, Kollia G, Randall D, Stoltz R, Berger S. Lack of
effect of multiple-dose gatifloxacin (GAT) on oral glucose tolerance (OGTT),
glucose and insulin homeostasis, and glyburide pharmacokinetics (PK) in
patients with type II non-insulin-dependent diabetes mellitus (NIDDM).
In: Program and abstracts of the 39th Interscience Conference on Antimicrobial
Agents and Chemotherapy, San Francisco, September 26–29, 1999. Washington,
D.C.: American Society for Microbiology, 1999:11; Schwarzbard L, Lodise
TP, Lomaestro BM, Smith R. Comparison of glucose intolerance (GI) between
gatifloxacin (G) and levofloxacin (L) in elderly, hospitalized patients.
In: Program and abstracts of the 45th Interscience Conference on Antimicrobial
Agents and Chemotherapy, Washington, D.C., December 16–19, 2005. Washington,
D.C.: American Society for Microbiology, 2005:463). These studies yielded
conflicting conclusions regarding the effects of gatifloxacin on blood
glucose levels, but some reports strongly suggest the existence of a causal
relationref.
For example, one recent report described two patients in whom profound
hyperglycemia (glucose, 942 to 1456 mg/dl) developed shortly after gatifloxacin
therapy but who had no subsequent evidence of diabetesref.
The use of gatifloxacin among outpatients is associated with an increased
risk of in-hospital treatment for both hypoglycemia and hyperglycemia :
so it should not be used in diabetics and other high risk patients)ref
gemifloxacin mesylate (Factive®)
grepafloxacin (Raxar®)
: recalled because of QT-interval prolongationref1,
ref2
(Rubinstein E. History of quinolones and their side effects. Chemotherapy
2001;47:Suppl 3:3-8, 44)
sparfloxacin (Spara®,
Zagam®) : recalled because of QT-interval prolongationref1,
ref2
(Rubinstein E. History of quinolones and their side effects. Chemotherapy
2001;47:Suppl 3:3-8, 44)
tosufloxacin
trovafloxacin (Trovan®)
: recalled because of hepatotoxicityref1,
ref2.
ABT-492
Side effects :
fluoride causes cartilage alterations (use is forbidden during pregnancy
and in children) => bilateral acute or chronic Achilles
calcaneal tendinitis
=> tendon rupture, more common in patients over 60 years of age. The latency
period between the start of treatment and the appearance of the first symptoms
range from 1 to 510 days with a median of 6 days. Most patients recover
within 2 months after cessation of therapy, but 26% have not yet recovered
at followup.
relapse in patients who suffered juvenile epilepsy
photosensitivity (use sunglasses)
neurologic impairment
incidence of convulsions and anxiety due to action as GABAA
antagonists
nausea and vomiting
Simultaneous administration of antacids
containing magnesium
or aluminium
and ciprofloxacin or other quinolones decreases the gastrointestinal absorption
of those antibacterial agents due to drug-cation chelationref.
rifampin (Rifadin®, Rimactane®)
is a semisynthetic derivative of rifamycin B active against
Gram +ve Bacteria, Mycobacterium
tuberculosis
and some Gram -ve Bacteria. Rifampicin
acts quite specifically against the b subunit
of the bacterial RNA polymerase and apparently blocks the entry of the
first nucleotide which is necessary to activate the polymerase. It is effective
orally and crosses the blood-brain barrier, so it is useful for treatment
of bacterial meningitis.
CBR703 series compounds inhibit known catalytic activities of RNAP
(nucleotide addition, pyrophosphorolysis, and Gre-stimulated transcript
cleavage) but not translocation of RNA or DNA when translocation is uncoupled
from catalysis.
While screening for a new broad-spectrum antibiotic, J&J researchers
discovered that a class of compounds called diarylquinolines worked
against
Mycobacteria smegmatis : chemical tinkering led them to
the even more potent R207910. It potently inhibits both drug-sensitive
and drug-resistant
Mycobacterium tuberculosis in vitro (MIC 0.06
µg/ml). In mice, R207910 exceeds the bactericidal activities of isoniazid
and rifampin by at least 1 log. As expected, resistance to R207910 developed
when given to mice as a monotherapy, but the J&J team's experiments
with mice have convinced leading TB researchers that swapping the drug
for 1 of the 3 in the most popular triple-drug combination now used would
delay development of resistant strains. Substitution of drugs included
in the WHO's first-line tuberculosis treatment regimen (rifampin, isoniazid
and pyrazinamide) with R207910 accelerates bactericidal activity, leading
to complete culture conversion after 2 months of treatment in some combinations,
about half the time it takes using the standard treatmen. A single dose
of R207910 inhibits mycobacterial growth for 1 week. Plasma levels associated
with efficacy in mice are well tolerated in healthy human volunteersref.
Human versions of the synthase are not affected by the drug and initial
studies in humans show that injections are safe, at least for short periods
of time. Trials in people who are actively sick are now under way, although
it will be many years before the drug makes it to the market. One of the
drugs in the standard tuberculosis cocktail does not mix well with many
HIV drugs, but a regimen with compound J would be fine. Another potential
bonus is that the compound may be useful against latent tuberculosis, as
it kills even when the bacteria are not actively reproducing. Although
the outbreaks of multidrug-resistant tuberculosis (MDR-TB) that afflicted
New York City in the 1990s were relatively minor when compared to the burden
of global tuberculosis [HN1]ref1,
ref2,
they served to raise public and political awareness. The result was that
for the first time TB control was included on the agenda of the G8 economic
summit meetings. The world's leaders lent their support to that of nongovernmental
organizations, such as the Global Alliance for TB Drug Development (GATDD)
and the WHO, by encouraging industry and academia to engage in the development
of new drugs to treat this chronic respiratory disease. This was a crucial
event given that TB claims up to 2 million lives annually worldwide, blights
myriad communities principally in developing countries, and that no new
TB drugs have been discovered in the past 40 yearsref.
The current treatment for TB recommended by WHO--known as directly observed
therapy short-course (DOTS)--requires patients to adhere to a 3- or 4-drug
regimen comprising isoniazid, rifampin, pyrazinamide, and/or ethambutol
for a minimum of 6 months. Many patients fail to complete therapy because
of drug side effects and the complicated drug regimen, resulting in relapse--often
in the form of MDR-TB, which is even more difficult to treat. An ideal
new TB drug should be highly active, so that treatment duration can be
reduced to <3 months; it should kill the persistent bacilli that might
otherwise reactivate later in life; and it must show activity against MDR-TB
strains. Optimally, a new therapeutic agent would be specific for Mycobacterium
tuberculosis and also compatible with existing TB drugs, because combination
therapy will remain mandatory to combat this major killerref.
Its lead compound was identified by adopting a medium-throughput screening
approach using live mycobacteria rather than the more popular target-based,
high-throughput screening that uses robotics to screen millions of compounds
for inhibitors of critical functions such as key enzyme activities. This
proved a very astute decision because it avoided problems with drug permeability
(which always affect the target-based screens at a later stage) by identifying
active compounds that freely entered the mycobacteria. After optimization
by synthetic chemistry, the investigators were left with 20 interesting
drug candidates; of these, R207910 showed the best activity profile. R207910
is bactericidal and exquisitely active against a broad range of mycobacteria
[HN11], displaying little or no activity against the other microorganisms
tested. Crucially, R207910 is active against both the drug-sensitive and
drug-resistant forms of M. tuberculosis. This organic compound of
555.51 daltons, which contains both planar hydrophobic moieties and hydrogen-bonding
acceptor and donor groups, displays perfect drug-like features that satisfy
most of Lipinski's rules for good drug candidatesref.
Pharmacokinetic and pharmacodynamic studies in different animal models
have confirmed the excellent drug-like properties of diarylquinolines.
To identify the target of R207910, mutants of M. tuberculosis were
isolated and the related faster-growing organism M. smegmatis that
were resistant to R207910, and characterized by whole-genome sequencing.
2 different missense mutations in the atpE gene, which encodes the C subunit
of ATP synthase, the enzyme that uses the transmembrane proton-motive force
to generate ATP for the cellref. Model of the mycobacterial ATP synthase showing the position of mutations
that confer resistance to the diarylquinoline drug R207910ref.
ATP synthase has 2 major structural domains, F0 and F1,
that act as a biological rotary motorref.
F1 is composed of 9 subunits (a3,
b3,
g,
d,
e)
and is located in the cytoplasm, where it generates ATP. F0
spans the cytoplasmic membrane and contains 13 to 15 subunits (a, b2,
c9-12) arranged as a symmetrical disc. The F0 and
F1 domains are linked by subunits
g,
e,
d,
and b2. Rotation of the transmembrane disc and the central stalk
is driven by the proton-motive force. The c subunit is an a-helical
hairpin structure with a short connecting loop. Notably, the A63P mutation
is very near E60, the glutamic acid residue whose carboxyl group is protonated
during proton translocation. The proton-motive force fuels the rotation
of the transmembrane disk and the central stalk, which in turn modulates
the nucleotide affinity in the catalytic b subunit,
leading to the production of ATP. The c subunit has a hairpin structure
with 2 a helices and a short connecting loop.
The 2 mutations affect the membrane-spanning
a
helices of the ATP synthase c subunit and may restrict binding of R207910
to the enzyme. Although biochemical confirmation is now required, it is
possible that the drug impedes assembly of the mobile disk or interferes
with its rotational properties, leading to inadequate synthesis of ATP.
A puzzling feature of R207910 is its exceptional specificity for mycobacteria.
ATP synthase is a ubiquitous enzyme found in most living organisms, including
humans. There is very limited sequence similarity between the mycobacterial
and human AtpE proteins, which bodes well for the safety of the compound,
as borne out by the phase I study in human volunteers. The mycobacteria-specific
activity of R207910ref
may also be the consequence of limited sequence similarity among bacterial
AtpE proteins. However, those antitubercular agents that show highly restricted
activity (such as isoniazid, ethionamide, and pyrazinamide) are all prodrugs
requiring activation by a mycobacterial enzymeref.
Although its chemical structure gives no clues to potential activation
sites, R207910 may also prove to be a prodrug. Mouse studies already show
that this compound can greatly shorten the duration of therapy, both alone
and in association with current antitubercular agents. Furthermore, the
equally remarkable activity of R207910 against M. ulcerans--the
agent of an emerging human disease called Buruli ulcerref,
for which surgery is the only cure--also raises expectations for a safer
treatment for this disfiguring afflictionref.
xenobiotics interfering with intermediate
metabolism (anti-metabolites or
growth
factor analogs)
sulfonamides (bacteriostatic).
They were introduced as chemotherapeutic agents by Domagk,
Mietsch and Klarer in 1935, who showed that one of these compounds (the
substituted
sulfanilamide ...
... derived from the intracellular degradation of the bacterial stain
4-sulfonamide-2',4'-diaminobenzol or red Prontosil ...
...) had the effect of curing mice with infections caused by
b-hemolytic
Streptococcus
spp.. Chemical modifications of the compound sulfanilamide gave compounds
with even higher and broader antibacterial activity. Bacteria which
are almost always sensitive to the sulfonamides include Gram
+ve Streptococci (b-hemolytic
Streptococci
and
Streptococcus pneumoniae (even if some Streptococci can assume
folate from the environment, bypassing the synthesis blockage)) and Gram
-ve Bacteria (E. coli, Neisseria meningitidis). They
cross the blood-brain barrier.
rapidly absorbed and rapidly eliminated sulfonamides
sulfisoxazole diolamine (Gantrisin®, ...; Pediazole®
in combination with erythromycin ethylsuccinate for otitis media; ? in
combination with phenazopyridine for UTIs)
sulfacetamide (AK-Sulf®, Bleph-10®,
Cetamide®, Isopto Cetamide®, Klaron®,
Sebizon®, Sodium Sulamyd®, Sulf-10®,
Sultrim®... ; Sulfacet-R® in combination
with sulfur)
silver sulfadiazine (SSD) (SSD®, Silvadene®,
...)is the most commonly used topical antibacterial agent for the treatment
of burn wounds. It has many clinical advantages, including a broad spectrum
of antimicrobial activity, low toxicity, and minimal pain on application.
The current formulation of silver sulfadiazine contains a lipid soluble
carrier, polypropylene glycol, that has certain disadvantages, including
pseudo-eschar formation and the need for twice daily application. A new
formulation of silver sulfadiazine in a water soluble gel, poloxamer 188,
can be applied once a day and its water solubility allow easy application
and removal. Silver compounds are used widely as effective antimicrobial
agents to combat pathogens (bacteria, viruses and eukaryotic microorganisms)
in the clinic and for public health hygiene. Silver cations (Ag+)
are microcidal at low concentrations and used to treat burns, wounds and
ulcers. Ag is used to coat catheters to retard microbial biofilm development.
Ag is used in hygiene products including face creams, "alternative medicine"
health supplements, supermarket products for washing vegetables, and water
filtration cartridges. Ag is generally without adverse effects for humans,
and argyria
is rare and mostly of cosmetic concern.Resistance to silver compounds as
determined by bacterial plasmids and genes has been defined by molecular
genetics. Silver resistance conferred by the Salmonella plasmid
pMGH100 involves nine genes in three transcription units. A sensor/responder
(SilRS) two-component transcriptional regulatory system governs synthesis
of a periplasmic Ag(I)-binding protein (SilE) and two efflux pumps (a P-type
ATPase (SilP) plus a 3-protein chemiosmotic RND Ag(I)/H+ exchange system
(SilCBA)). The same genes were identified on five of 19 additional IncH
incompatibility class plasmids but thus far not on other plasmids. Of 70
random enteric isolates from a local hospital, isolates from catheters
and other Ag-exposed sites, and total genomes of enteric bacteria, 10 have
recognizable sil genes. The centrally located 6 genes are found and functional
in the chromosome of Escherichia
coliK-12,
and also occur on the genome of E. coli O157:H7. The use of molecular
epidemiological tools will establish the range and diversity of such resistance
systems in clinical and non-clinical sources
sulfadoxine (Fansidar®
in combination with pyrimethamine)
sulfamazole
sulfamazone
sulfamethizole (Thiosulfil Forte®)
sulfametopirazine
sulfametoxypiridazine
sulfametrol
succinylsulfathiazole
Side effects : renal and hepatic toxicity
(they may cause kernicterus in newborns by displacing bilirubin
from plasma proteins in the face of increased bilirubin production from
fetal erythrocyte turnover, decreased bilirubin conjugation, acidosis,
and decreased blood-brain barrier), agranulocytosis, thrombocytopenia,
acquired
aplastic anemia,
hemolytic anemia in G6PD- patients, GI toxicity, Steven-Johnsons's
syndrome
=> Lyell's
syndrome.
p-aminosalicylic acid
(PAS) competes with p-aminobenzoic acid (PABA)
pyrimethamine / 2,4-diamino-5-(p-chlorophenyl)-6-ethyl-
pyrimidine (Fansidar® in combination with sulfadoxine;
Maloprim®, Deltaprim® in combination with
dapsone)
tetroxyprim
trimethoprim (TMP) (Trimplex®,
Proloprim®, ...) (bacteriostatic)
inhibits bacterial DHF reductase. It is often administered together with
bacteriostatic
sulfamethoxazole
as co-trimoxazole / cotrimoxazole /
TMP/SMX (Bactrim®, Cotrim®, Cofatrim®,
Primsol®, Septra®, ...), becoming bactericidal
against Gram -ve Bacteria; Polytrim®
in combination with
polymyxin B
albomycin is an analog of ferrichrome, made
by some Fungi.
ClpP (a core unit of a major bacterial protease complex) inhibitors
: acyldepsipeptides have antibacterial activity against Gram-positive
bacteria in vitro and in several rodent models of bacterial infection.
The acyldepsipeptides are active against isolates that are resistant to
antibiotics in clinical application. Clp is usually tightly regulated and
strictly requires a member of the family of Clp-ATPases and often further
accessory proteins for proteolytic activation. Binding of acyldepsipeptides
to ClpP eliminates these safeguards. The acyldepsipeptide-activated ClpP
core is capable of proteolytic degradation in the absence of the regulatory
Clp-ATPases.
Such uncontrolled proteolysis leads to inhibition of bacterial cell division
and eventually cell deathref
Adverse events :
direct toxicity
cardiac effects - prolongation of the QTc intervalref
renal toxicityref1,
ref2.
Very ill patients may have impaired absorption, altered clearance due to
renal dysfunction (increased risk of adverse events, increased antibiotic
doses are often required in burn patients)ref
superinfection
antibiotics can change the normal microbial floraref,
allowing overgrowth of opportunistic infections (e.g. Candida spp.
in the gastrointestinal tract)ref
Leading parenteral antibiotic products in the global hospital market for
prophylaxis and therapy in USA and 5 European countries
Current status of antibacterial resistance in the ICU (NNIS, 2002 vs
1997-2001)ref
:
The quantity of antimicrobials used in food animals in Denmark has
declined 54% from peak use between 1994 and 2001. Before the programme
began, most pigs and broiler chickens in Denmark were given antimicrobials,
such as avilamycin, avoparcin, tylosin, streptogramins
and virginiamycin, for most of their lives. After withdrawal, average
use declined to 0.4 days in broiler chickens (with life span of around
42 days) and 7.9 days in pigs (with life span of around 170 days). Pork
production
in Denmark has continued to increase, and effects on poultry production
were small. Ending the use of the above antimicrobials has greatly reduced
the reservoir of resistant Enterococcus
faecium
in the food animal reservoir, thus reducing the reservoir of resistance
genes. For example, resistance to avilamycin, avoparcin, and streptogramins
in Enterococcus faecium isolates from broiler chickens declined
from 60-80% before withdrawal of antimicrobials to only 5-35% after.
The carboxylic ionophoresref
are open-chained oxygenated heterocyclic rings with a single terminal carboxyl
group of moderate molecular weight (200-2000). It is a drug for use in
animals only, and there is no comparable drug or drug category for humans.
Ionophores form lipid-soluble complexes with polar cations (K+,
Na+, Ca2+ and Mg2+), have a diverse antibacterial
spectra and are produced by fungi, predominantly Streptomyces sp.
These compounds are used as anticoccidial and growth promotant feed additives.
Clinical pathology of ionophore-induced toxicityref1,
ref2,
ref3,
ref4,
ref5
includes elevated enzyme levels of muscle origin such as aspartate transaminase
(AST) and creatine phosphokinase (CPK). Other serum enzymes that may be
elevated are lactic dehydrogenase (LDH) and alkaline phosphatase. Additonally,
there may be elevations in blood urea nitrogen and bilirubin. Serum calcium
and potassium levels may fall to life-threatening levels in horses. Hemoconcentration
may also occur. The ionophores are generally safe at prescribed levels
in intended species. Certain management situations increase the possibility
of toxicoses including overdose, mixing errors, premix consumption, and
misuse in non-target species such as horses, adult turkeys, and dogs. Concurrent
administration of other drugs, including chloramphenicol, erythromycin,
sulfonamides and cardiac glycosides, can potentate ionophore toxicosis.
calcium ionophores
clearly have effects in human cells. Binding of calcium can produce the
signs and symptoms of hypocalcemia
and can upregulate or downregulate cellular functions based on the role
of calcium in such processesref1,
ref2.
lasalocid / X-537A is a divalent ionophore
used in broiler chickens (Avatec®) for the prevention of
coccidiosis caused by Eimeria sp. and in cattle (Bovatec®)
for improved feed efficiency and increased rate of weight gain. It gets
into laying hens and consequently eggs through batches of chicken feed
which have been contaminated by accident : 12% of UK eggs tested contained
residues. It is unclear if the levels in the eggs would cause clinical
or subclinical effects in humans. However, rules of the European Union
have banned lasalocid from being added to feed that is given to laying
hens. Although this problem may have existed before, the maximum level
of lasalocid reported in eggs has risen significantly over the past year
from 620 mg/kg in 2002 to 3450 in 2003. 2 of
the 250 samples contained levels above 3000 mg/kg.
People with cardiac arrhythmia, children, and adults who eat 3 or 4 eggs
a day are most at risk from the drug (babies under 6 months should not
be fed eggs because of the potential risk of allergic reactions), which
has been linked to increased heart and breathing rates, paralysis and even
sudden adult death syndrome in poultry. Consumers should be aware of the
potential danger and limit their daily egg intake. Eat organic if you can
and certainly give organic eggs to children, and 2 eggs in one day would
be the maximum you should have
Spray for poultry processing companies to apply to contaminated surface
of raw poultry :
10% trisodium phosphate (TSP)
0.1% acidified sodium chlorite (ASC)
0.1 and 0.5% cetylpyridinium chloride (CPC) (Cecure®),
used since the 1930s in mouthwashes and throat lozenges, is effective against
Campylobacter
jejuniref,
Salmonella
spp.,
Escherichia
coli,
and Listeria spp..
It has no taste or smell, does not change the color of meat, and leaves
a residue on foods only if they contain a lot of surface fat
1% Tween 80
water (50°C at application)
Scientists of the Kosan Bioscience
have overcome an important hurdle in the race to develop new antibiotics:
they have made bacteria efficiently churn out chemicals that could prove
to be useful drugs. Over the past few decades, bacteria have evolved to
resist our antibiotics. As a result, hospitals have seen a dramatic rise
in drug-resistant infections, many of which are fatal. To come up with
new antibiotics, scientists often work with the natural chemical defences
of fungi and bacteria, altering these natural antibiotics to make new ones.
Researchers have also attempted to genetically engineer bacteria to pump
out new chemicals directly. Although chemicals produced this way have not
yet been used to fight human disease, the approach has produced some promising
compounds, including :
lantibiotics are ribosomally-synthesised
antimicrobial peptides produced by Gram-positive bacteria that are characterised
by the presence of lanthionine and/or methyllanthionine residues.
Other unusual post-translationally modified amino acids, most frequently
dehydroalanine
and dehydrobutyrine, can also be present. While it has been frequently
suggested that these peptides have the potential to be utilised in a wide
range of medical applications, to date no actual therapeutic applications
have been convincingly described. More recently, however, they have been
the focus of much attention as a consequence of improved biotechnological
capabilities, an improved understanding of lantibiotic biosynthesis and
mode of action, and their high specific activity against multi-drug resistant
bacteria. Rational mutagenesis strategies ('intelligenetics') have been
implemented to alter individual residues with a view to ultimately widening
the active pH range, improve stability, and enhance binding to cell wall
targets with the ultimate aim of optimising their antimicrobial activity.
It is hoped that as a consequence of this improved knowledge the most suitable
application of individual lantibiotics will become apparent. It should
also prove possible, in the near future, to generate tailor-made lantibiotics
and utilise biosynthetic enzymes to incorporate modified amino acids into
non-lantibiotic peptides. In the shorter term, the extensive characterisation
of lantibiotics will be instrumental in reassuring drug industry regulators
of their safety and facilitate the widespread application of these novel
antimicrobial agents in medicineref.
The antimicrobial action of bacteriocins from Gram-positive bacteria is
based on interaction with the cytoplasmic membrane of sensitive bacteriaref
:
nisin : a cationic, polycyclic bacteriocin of
34 residues, including several unusual dehydro residues and thioether-bridged
lanthionines. Models based on studies with artificial membrane systems
propose that it forms wedge-like poration complexes in the membrane by
electrostatic interaction between the positively charged C terminus of
the peptide and anionic membrane phospholipids. Nisin can also permeabilise
membranes via a targeted mechanism by using lipid II, the bactoprenol-bound
precursor of the bacterial cell wall, as a docking molecule. Another consequence
of binding with lipid II is the inhibition of peptidoglycan biosynthesis.
mersacidine and actagardine
also form a complex with lipid II, but binding only blocks the incorporation
of lipid II into peptidoglycan, resulting in slow cell lysis rather than
pore formation.
plantaricin C and pediocin
PD-1 share a conserved sequence motif, which is most probably involved
in the binding of these bacteriocins to lipid II, with mersacidine and
actagardine. Although pediocin PD-1 and plantaricin C may inhibit peptidoglycan
biosynthesis, pore formation is rather due to electrostatic interaction
between the positively charged unbridged N-terminus and anionic
phospholipids in the cytoplasmic membrane of sensitive cells.
epilancin 15X, a novel lantibiotic from
a clinical strain of Staphylococcus epidermidisref
But scientists have stumbled in trying to get bacteria to spit out chemicals
belonging to a class known as polyketides.
Polyketides are molecules that contain large rings of carbon and oxygen
atoms, and include the well-known antibiotic erythromycin. DNA sequences
that produce bits of the proteins that make polyketides were taken from
several different bacteria, mixed and matched nside Escherichia coli
bacteria.
This much has been done before, but the hard part was getting the resulting
bits of protein to combine into a functioning polyketide-making machine.
Polyketide proteins are very large, so it is particularly difficult to
get the components to attach together. To achieve this, special sequences
were added to the ends of their genetic fragments that in turn made the
protein fragments 'sticky'. This meant the protein bits joined up "like
Lego building blocks", resulting in new proteins conformations and new
polyketidesref.
The team has yet to test whether these polyketides have antibiotic powers.
But they anticipate that at least some will be useful. A few natural polyketides
attack cancer cells, so some of the bioengineered ones might have anti-cancer
properties too.
In-vitroantibiotic-induced endotoxin release may depend
on antibiotic class, presence of serum, type of organism, site of antibiotic
action and Gram-stain. Endotoxin release may be different in late or early
lysis, proportional to the number of killed pathogens. Morphology of bacteria
may have an impact on endotoxin release and phagocytosis. Antibiotic-treated
animals may show higher endotoxin levels with a higher survival rate than
untreated animals. Plasma endotoxin may increase despite decreasing bacteremia.
There may be a similar killing rate by different antibiotics but a difference
in endotoxin release. Intestinal endotoxin does not necessarily correlate
to the level of gram-negative bacteria. However, the alteration of the
gut content by pretreatment may be associated with reduced endotoxemia
and increased survival. Antibiotic-induced endotoxin release may be different
depending on the type of infection, the location of infection, the virulence
of strains, Gram-stain, mode of application and dosage of antibiotic. Different
antibiotics may induce the release of different forms of endotoxin which
may be lethal for sensitized animals. The combination of antibiotics with
inhibitors of endotoxin or the pro-inflammatory response may be responsible
for increased survival by decrease of endotoxin release. The clinical significance
of antibiotic-induced endotoxin release is documented only in a few clinical
disorders, e.g., meningitis, urosepsis. The difference in endotoxin release
by PBP 2-specific antibiotics, e.g., imipenem, and PBP 3-specific antibiotics,
e.g., ceftazidime, may not be visible in each study. Patients with increased
MOF scores may profit from treatment with antibiotics known to decrease
endotoxin. In conclusion, the clinical significance of antibiotic-induced
endotoxin release remains to be clarified. Type of pathogen and its virulence
may be more important than recently suggested. gram-positive pathogens
were just recently recognized as an important factor for the development
of the host response. In case of FUO in ICU patients either failure of
treatment, e.g., failure of source control in IAI, or a side effect of
antibiotic treatment, e.g., endotoxin release, should be considered as
a cause of the feverref.